Literature DB >> 19827001

Dominance and gene dosage balance in health and disease: why levels matter!

Reiner A Veitia1, James A Birchler.   

Abstract

The classical concept of genetic dominance is a simplification of a more quantitative reality. This is clearly exemplified by aneuploid syndromes, of which the best known case is trisomy 21. Moreover, there is an increasing number of clinical conditions due to reduced dosage (haploinsufficiency) of genes encoding transcription factors and other proteins involved in signal transduction and macromolecular complexes. In such genetic diseases, a high degree of phenotypic variability is observed, which calls for an explanation. The sources of dominance are heterogeneous and difficult to cover in a brief review. Here, we will focus on the molecular bases of dosage-sensitive syndromes from the perspective of the gene dosage balance hypothesis, which postulates that stoichiometric alterations of macromolecular complexes or cellular networks are responsible for dominant phenotypes, because of the existing non-linear relationships between the genotypic and phenotypic values with which they are associated.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 19827001     DOI: 10.1002/path.2623

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  28 in total

1.  Familial isolated clubfoot is associated with recurrent chromosome 17q23.1q23.2 microduplications containing TBX4.

Authors:  David M Alvarado; Hyuliya Aferol; Kevin McCall; Jason B Huang; Matthew Techy; Jillian Buchan; Janet Cady; Patrick R Gonzales; Matthew B Dobbs; Christina A Gurnett
Journal:  Am J Hum Genet       Date:  2010-07-09       Impact factor: 11.025

2.  FAS haploinsufficiency is a common disease mechanism in the human autoimmune lymphoproliferative syndrome.

Authors:  Hye Sun Kuehn; Iusta Caminha; Julie E Niemela; V Koneti Rao; Joie Davis; Thomas A Fleisher; João B Oliveira
Journal:  J Immunol       Date:  2011-04-13       Impact factor: 5.422

3.  Constant splice-isoform ratios in human lymphoblastoid cells support the concept of a splico-stat.

Authors:  Marcel Kramer; Klaus Huse; Uwe Menzel; Oliver Backhaus; Philip Rosenstiel; Stefan Schreiber; Jochen Hampe; Matthias Platzer
Journal:  Genetics       Date:  2011-01-10       Impact factor: 4.562

Review 4.  Gene balance hypothesis: connecting issues of dosage sensitivity across biological disciplines.

Authors:  James A Birchler; Reiner A Veitia
Journal:  Proc Natl Acad Sci U S A       Date:  2012-08-20       Impact factor: 11.205

5.  A Loss or a Gain, Is It Not All the Same?

Authors:  Martin Poot
Journal:  Mol Syndromol       Date:  2016-02-05

Review 6.  Neuropathy- and myopathy-associated mutations in human small heat shock proteins: Characteristics and evolutionary history of the mutation sites.

Authors:  Rainer Benndorf; Jody L Martin; Sergei L Kosakovsky Pond; Joel O Wertheim
Journal:  Mutat Res Rev Mutat Res       Date:  2014-03-06       Impact factor: 5.657

7.  Mutations in Mediator Complex Genes CDK8, MED12, MED13, and MEDL13 Mediate Overlapping Developmental Syndromes.

Authors:  Martin Poot
Journal:  Mol Syndromol       Date:  2019-08-16

8.  5q31 Microdeletions: Definition of a Critical Region and Analysis of LRRTM2, a Candidate Gene for Intellectual Disability.

Authors:  W Kleffmann; A M Zink; J A Lee; J Senderek; E Mangold; U Moog; G A Rappold; E Wohlleber; H Engels
Journal:  Mol Syndromol       Date:  2012-07-25

Review 9.  Mechanisms of Origin, Phenotypic Effects and Diagnostic Implications of Complex Chromosome Rearrangements.

Authors:  Martin Poot; Thomas Haaf
Journal:  Mol Syndromol       Date:  2015-08-15

10.  Multiple Small Supernumerary Marker Chromosomes Resulting from Maternal Meiosis I or II Errors.

Authors:  Ron Hochstenbach; Beata Nowakowska; Marianne Volleth; Amber Ummels; Anna Kutkowska-Kaźmierczak; Ewa Obersztyn; Kamila Ziemkiewicz; Claudia Gerloff; Denny Schanze; Martin Zenker; Petra Muschke; Ina Schanze; Martin Poot; Thomas Liehr
Journal:  Mol Syndromol       Date:  2015-10-31
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.